Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

Clinical trial NCT04979988 · COMPLETED

Trial details

NCT number: NCT04979988
Sponsor: Pfizer
Status: COMPLETED
Study type: OBSERVATIONAL

ALK-positive Non-small-cell Lung Cancer

Start date: 2021-08-02
Primary completion: 2021-12-09
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.